Case report: Posterior reversible encephalopathy syndrome, an adverse effect of lenvatinib and pembrolizumab combination therapy, in a patient with advanced endometrial cancer

BACKGROUND: Lenvatinib-pembrolizumab combination (LEAP) is an approved therapy in Japan for advanced endometrial cancer, based on the data from the KEYNOTE-775 clinical trial. We report a case of posterior reversible encephalopathy syndrome (PRES) in a patient who received LEAP therapy for advanced...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsuura, Yuki, Nishida, Haruka, Kosaka, Takashi, Shigekawa, Kazuyuki, Takasaki, Kazuki, Ichinose, Takayuki, Hirano, Mana, Hiraike, Haruko, Nagasaka, Kazunori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9895820/
https://www.ncbi.nlm.nih.gov/pubmed/36741713
http://dx.doi.org/10.3389/fonc.2022.1079716

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9895820/
https://www.ncbi.nlm.nih.gov/pubmed/36741713
http://dx.doi.org/10.3389/fonc.2022.1079716

Ejemplares similares